MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.83 (838.82% upside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Show:
DateFirmActionRatingPrice TargetActions
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Bank of America Corp.DowngradeNeutral -> Underperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015JPMorgan Chase & Co.Reiterated RatingNeutral$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Jefferies GroupLower Price TargetBuy$26.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Deutsche Bank AGDowngradeBuy -> Hold$58.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.28)$0.23$58.98 million$64.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q414($0.26)$0.06$59.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q4$0.08$0.11$49.18 million$51.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.14)($0.20)$48.60 million$43.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.35)($0.25)$33.58 million$27.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)$0.09($0.34)
Q2 20163($0.73)($0.01)($0.44)
Q3 20163($0.73)$0.15($0.37)
Q4 20163($0.78)($0.04)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateHeadline
07/01/16 07:35 PMAegerion Pharmaceuticals Inc. (AEGR) Jumps 6.04% on July 01 - Equities.com
07/01/16 02:21 PMShares Headed Up in Session: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Telanagana Press
07/01/16 10:19 AMNew Broker Ratings For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - FTSE News
06/30/16 02:21 PMUpdate on Stock Volatility for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
06/28/16 02:33 PMCovering the Bases on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Where is the Stock Going? - Press Telegraph
06/27/16 07:05 AMWere Analysts Bearish Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) This Week? - Engelwood Daily
06/25/16 02:20 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Shorts Decreased by 4.56% After Short Covering - Engelwood Daily
06/25/16 02:20 PMStrong Sell Calls Recommendations For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 0 - Investor Newswire
06/24/16 02:18 PMPrice Target Update on Aegerion Pharmaceuticals (NASDAQ:AEGR) - Trade Calls
06/24/16 10:05 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.05% on June 23 - Equities.com
06/22/16 07:29 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 5.56% on June 21 - Equities.com
06/21/16 02:18 PMUpdate in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by ... - Nasdaq
06/21/16 08:50 AMUpdate in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by Shareholders Foundation - [GlobeNewswire] - SAN DIEGO, June 21, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Massachusetts on behalf of certain purchasers of shares of Aegerion Pharmaceuticals, Inc. over alleged ...
06/19/16 07:05 AMStrong Buy Calls Count For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 1 - Investor Newswire
06/19/16 07:05 AMThis Weeks Broker Views For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Fiscal Standard
06/17/16 10:15 AMRatings Analysis of: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - News Oracle
06/17/16 10:15 AMAegerion Pharmaceuticals Inc. (AEGR) is Trading Higher on Unusual Volume for June 15 - Equities.com
06/16/16 02:21 PMCarbylan Therapeutics Inc (NASDAQ:CBYL) & Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Healthcare Trend ... - Wall Street 24
06/16/16 02:21 PMAnalyst Earnings Report: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), MGT Capital Investments, Inc. (NYSEMKT ... - Beacon Chronicle
06/16/16 10:40 AMAegerion CEO sees $500M in peak revenue after merger with Canadian firm -
06/16/16 06:02 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 28.57% on June 15 - Equities.com
06/15/16 07:24 PMAegerion Pharmaceuticals, Inc (AEGR) Stock Shoots over 30% on Merger with QLT Inc. - Bidness ETC
06/15/16 02:22 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 8.03% on June 13 - Equities.com
06/15/16 12:45 PMAegerion Pharmaceuticals (AEGR) Stock Surges on QLT Merger -
06/15/16 07:06 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 5.56% on June 14 - Equities.com
06/15/16 07:06 AMAegerion Pharmaceuticals Inc. (AEGR) Hits New 52-week Low During June 13 Session - Equities.com
06/15/16 07:06 AMQLT Inc. (QLTI), Aegerion Pharma (AEGR) Enter Strategic Merger Agreement - StreetInsider.com
06/15/16 06:15 AMAegerion and QLT announce merger plans -
06/15/16 06:09 AMAegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger - [at noodls] - June 7, 2016 CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative ...
06/12/16 02:21 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 6.25% on June 09 - Equities.com
06/11/16 02:21 PMAegerion Pharmaceuticals Inc. (AEGR) Hits New 52-week Low During June 09 Session - Equities.com
06/10/16 08:02 PMPre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
06/08/16 08:35 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 5.62% on June 07 - Equities.com
06/08/16 10:48 AMAEGERION PHARMACEUTICALS INC. (NASDAQ:AEGR) Financial Condition Compared to S&P 500 - CML News
06/07/16 07:55 PMAegerion Pharma (AEGR) Grants Stock Options Covering 10958 Shares - StreetInsider.com
06/06/16 04:21 PMETF’s with exposure to Aegerion Pharmaceuticals, Inc. : June 6, 2016 -
06/05/16 02:21 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Short Interest Decreased By 4.4% - HNN
06/02/16 08:18 PMStock Review and Earnings Check on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - HNN - Stock Review and Earnings Check on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) to report quarterly EPS of $-0.6. The company's next earnings report is expected to be ...and more »
06/02/16 10:58 AMMost recent Trading report: IDEXX Laboratories, Inc. (NASDAQ:IDXX) , Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Street Updates - Most recent Trading report: IDEXX Laboratories, Inc. (NASDAQ:IDXX) , Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)Street UpdatesOn 6/1/2016, IDEXX Laboratories, Inc. (NASDAQ:IDXX) highlighted upward shift of +0.70% or +0.61 points to $88.18. The company traded a volume of 1.12 million shares over average volume of 823.71 thousand shares. Trailing twelve month period, the firm ...and more »
06/01/16 08:25 PMAegerion Pharmaceuticals Inc. (AEGR) Jumps 8.43% on June 01 - Equities.com - Aegerion Pharmaceuticals Inc. (AEGR) Jumps 8.43% on June 01Equities.comAegerion Pharmaceuticals Inc. (AEGR) was among the biggest gainers on the Russell 2000 for Wednesday June 01 as the stock popped 8.43% to $1.93, representing a gain of $0.15 per share. Some 907,946 shares traded hands on 4,216 trades, compared ...and more »
06/01/16 03:02 PMAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/01/16 10:40 AMEarnings Expectations of the Stock: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Avnet, Inc. (NYSE:AVT) - Beacon Chronicle - Earnings Expectations of the Stock: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Avnet, Inc. (NYSE:AVT)Beacon ChronicleLast Trade: The Company closed its last session at $1.78 with the loss of -2.2%. The market capitalization of the company is $52.46 Million, with the average Volume of 817.47K. The stock currently has its 52-Week High range of $20.45 and 52-week low ...and more »
06/01/16 10:40 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 5.2% on May 30 - Equities.com - Aegerion Pharmaceuticals Inc. (AEGR) Jumps 5.2% on May 30Equities.comAegerion Pharmaceuticals Inc. (AEGR) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 5.2% to $1.82, representing a gain of $0.09 per share. Some 809,570 shares traded hands on 3,681 trades, compared with ...and more »
05/31/16 02:18 PMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) increased 5.20%: Big Lots Inc. (NYSE:BIG), Bottomline Technologies ... - KC Register - Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) increased 5.20%: Big Lots Inc. (NYSE:BIG), Bottomline Technologies ...KC RegisterOn 16 May, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced first quarter 2016 financial results. Q1 gaap loss per share $2.22. Q1 earnings per share view $-0.58,Q1 non-gaap loss per share $1.72. On Friday Aegerion Pharmaceuticals, Inc.
05/31/16 02:18 PMShare Rating Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - HNN - Share Rating Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 2.75 on shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). Covering analysts ...and more »
05/31/16 05:47 AMMost Recent Stocks Movements: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , Halozyme Therapeutics, Inc ... - Street Updates - Most Recent Stocks Movements: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , Halozyme Therapeutics, Inc ...Street UpdatesAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) accumulated +5.20%, closing at $1.82 after floating between $1.65 and $1.84. The company has market capitalization of $53.69M. It has twelve month low of $1.57 and twelve month high of $20.45. The recent ...Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Edged 5.20%: ESCO Technologies Inc. (NYSE:ESE), Merck & Co ...Benchmark Monitorall 2 news articles »
05/29/16 09:10 PMPerformance at a Glance on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - HNN - Performance at a Glance on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)'s stock has performed at various points in its past ...and more »
05/28/16 02:46 AMAegerion Pharmaceuticals Inc. (AEGR) Hits New 52-week Low During May 26 Session - Equities.com - Aegerion Pharmaceuticals Inc. (AEGR) Hits New 52-week Low During May 26 SessionEquities.comAegerion Pharmaceuticals Inc. (AEGR) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $1.61, Aegerion Pharmaceuticals Inc. dropped to $1.57 for a new 52-week low. By the closing bell, the ...and more »
05/27/16 09:39 PMBiotech New Lows: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Pfenex Inc. (NYSEMKT:PFNX), Cerecor Inc ... - KC Register - Biotech New Lows: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Pfenex Inc. (NYSEMKT:PFNX), Cerecor Inc ...KC RegisterOn 16 May, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) recorded total net product sales of $35.7 million in q1 of 2016. Aegerion Pharmaceuticals Inc says expect research and development expenses to decrease slightly in 2016 as compared to 2015.and more »
05/27/16 04:32 PMBroker Roundup For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Share Trading News - Broker Roundup For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)Share Trading News11/19/2013 – Aegerion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 110 price target on the stock. The share price of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was up +7.45% during the ...Aegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Shorts Decreased by 4.4% After Short CoveringThe Postall 3 news articles »
About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AEGR
  • CUSIP: 00767E10
Key Metrics:
  • Previous Close: $1.58
  • 50 Day Moving Average: $1.66
  • 200 Day Moving Average: $4.72
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $46.61M
  • Current Quarter EPS Consensus Estimate: $-3.41 EPS
Additional Links:
Aegerion Pharmaceuticals (NASDAQ:AEGR) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha